D0093 | Oxaprozin
M
M01AE12 Oxaprozin
[M01AE] Propionic acid derivatives
[M01A] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS, NON-STEROIDS
[M01] ANTIINFLAMMATORY AND ANTIRHEUMATIC PRODUCTS
[M] Musculoskeletal system
| Pictogram | Signal | Statements | Precautionary Statement Codes |
|---|---|---|---|
  |
Warning |
Aggregated GHS information provided by 3 companies from 3 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies. H302 (33.33%): Harmful if swallowed [Warning Acute toxicity, oral] H315 (33.33%): Causes skin irritation [Warning Skin corrosion/irritation] H319 (33.33%): Causes serious eye irritation [Warning Serious eye damage/eye irritation] H411 (33.33%): Toxic to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] H412 (33.33%): Harmful to aquatic life with long lasting effects [Hazardous to the aquatic environment, long-term hazard] Information may vary between notifications depending on impurities, additives, and other factors. The percentage value in parenthesis indicates the notified classification ratio from companies that provide hazard codes. Only hazard codes with percentage values above 10% are shown. |
P264, P270, P273, P280, P301+P312, P302+P352, P305+P351+P338, P321, P330, P332+P313, P337+P313, P362, P391, and P501; (The corresponding statement to each P-code can be found at the GHS Classification page.) |
| .beta.-(4,5-Diphenyloxazol-2-yl)propionic acid | 2-OXAZOLEPROPIONIC ACID, 4,5-DIPHENYL- | 2-Oxazolepropanoic acid, 4,5-diphenyl- |
| 2-Oxazolepropanoic acid,5-diphenyl- | 2-Oxazolepropionic acid,5-diphenyl- | 21256-18-8 |
| 256O188 | 3-(4, 5-Diphenyl-2-oxazolyl)propenoic acid | 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid |
| 3-(4,5-Diphenyl-1,3-oxazol-2-yl)propanoic acid # | 3-(4,5-Diphenyl-2-oxazolyl)propanoic acid | 3-(4,5-Diphenyl-2-oxazolyl)propenoic acid |
| 3-(4,5-Diphenyl-2-oxazolyl)propionic acid | 3-(4,5-Diphenyl-oxazol-2-yl)-propionic acid | 3-(4,5-Diphenyloxazol-2-yl)propanoic acid |
| 3-(diphenyl-1,3-oxazol-2-yl)propanoic acid | 4, 5-Diphenyl-2-oxazolepropionic acid | 4,5-Diphenyl-2-oxazolepropanoic acid |
| 4,5-Diphenyl-2-oxazolepropionic acid | 4,5-Diphenyloxazole-2-propionic acid | 4,5-diphenyloxazole-2-propanoic acid |
| 4.5-Diphenyl-2-oxazolepropanoic acid|||Daypro | A815225 | AB0011812 |
| AB00514024 | AB00514024_08 | AB00514024_09 |
| AC-26512 | AK-84489 | AKOS000206807 |
| ANW-63377 | Actirin | Alvo |
| B1804 | BCP28431 | BDBM50002861 |
| BIDD:GT0438 | BIDD:PXR0149 | BPBio1_001122 |
| BRD-K25394294-001-05-7 | BRD-K25394294-001-08-1 | BRN 1083168 |
| BSPBio_001020 | BSPBio_002696 | C07356 |
| C18H15NO3 | CAS-21256-18-8 | CCG-36508 |
| CHEBI:7822 | CHEMBL1071 | CPD000058286 |
| CS-7975 | CTK7J3117 | D00463 |
| DB00991 | DSSTox_CID_25118 | DSSTox_GSID_45118 |
| DSSTox_RID_80684 | DTXSID1045118 | Danoprox |
| Daypro | Daypro (TN) | Dayrun |
| Deflam | Durapro | Duraprost |
| EINECS 244-296-1 | EN300-25629 | EU-0100944 |
| FT-0638104 | GTPL7252 | HMS1571C22 |
| HMS1922P17 | HMS2051L15 | HMS2093O08 |
| HMS2098C22 | HMS3262N10 | HMS3393L15 |
| HMS3652H17 | HMS3715C22 | HMS566H22 |
| HSDB 7586 | HY-B0808 | J-013955 |
| J10396 | K-6109 | KBio3_001916 |
| KBioGR_001722 | KS-00000ULR | KS-5196 |
| LP00944 | LS-100216 | Lopac-O-9637 |
| Lopac0_000944 | MCULE-7099031811 | MFCD00215977 |
| MHJ80W9LRB | MLS000759535 | MLS001424072 |
| Maybridge1_008800 | NC00214 | NCGC00014711 |
| NCGC00014711-01 | NCGC00014711-02 | NCGC00014711-03 |
| NCGC00014711-04 | NCGC00014711-05 | NCGC00014711-06 |
| NCGC00014711-07 | NCGC00014711-08 | NCGC00014711-09 |
| NCGC00014711-10 | NCGC00014711-11 | NCGC00014711-14 |
| NCGC00014711-15 | NCGC00094249-01 | NCGC00094249-02 |
| NCGC00094249-03 | NCGC00094249-04 | NCGC00094249-05 |
| NCGC00094249-06 | NCGC00094249-07 | NCGC00261629-01 |
| NCI310839 | NCI60_002681 | NCIStruc1_000799 |
| NCIStruc2_000787 | NSC 310839 | NSC-310839 |
| NSC-758949 | NSC310839 | NSC758949 |
| O 9637 | O0377 | OFPXSFXSNFPTHF-UHFFFAOYSA-N |
| Oprea1_509470 | Oxapro | Oxaprozi |
| Oxaprozin (JP17/USAN/INN) | Oxaprozin [USAN:BAN:INN:JAN] | Oxaprozin [USAN:USP:INN:BAN:JAN] |
| Oxaprozin, United States Pharmacopeia (USP) Reference Standard | Oxaprozin, solid | Oxaprozin,(S) |
| Oxaprozina | Oxaprozina [INN-Spanish] | Oxaprozine |
| Oxaprozine [INN-French] | Oxaprozinum | Oxaprozinum [INN-Latin] |
| Oxaprozinum;Wy21743 | Pharmakon1600-01505267 | Prestwick0_001060 |
| Prestwick1_001060 | Prestwick2_001060 | Prestwick3_001060 |
| Q1749609 | SAM001246770 | SBB053166 |
| SBI-0050918.P002 | SC-13926 | SCHEMBL3286 |
| SMR000058286 | SPBio_001652 | SPBio_002940 |
| SPECTRUM1505267 | SR-01000076053 | SR-01000076053-1 |
| SR-01000076053-3 | SR-01000076053-7 | SR-01000076053-9 |
| ST50949623 | SW197319-4 | Spectrum2_001696 |
| Spectrum3_001078 | Spectrum4_001231 | TC-152122 |
| Tox21_110059 | Tox21_110059_1 | Tox21_500944 |
| UNII-MHJ80W9LRB | Voir | WY 21743 |
| WY-21,743 | WY-21743 | Walix |
| Wy21743 | Xopane | Z217102860 |
| ZINC49643479 | beta-(4,5-Diphenyloxazol-2-yl)propionic acid | oxaprosin |
| oxaprozin | s4230 |